NCT-58

SKU: orb1297741

Description

NCT-58 is a C-terminal HSP90 inhibitor that suppresses the HER family and Akt phosphorylation without triggering the heat shock response. It demonstrates anti-tumor efficacy by inducing apoptosis in HER2-positive cells and eliminating trastuzumab-resistant breast cancer stem-like cells in vitro.

Research Area

Cell Biology, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 2411429-33-7
• MW: 466.57
• Purity: 99.60% (May vary between batches)
• Formula: C₂₇H₃₄N₂O₅
• SMILES: COc1cc(NC(=O)c2ccc3OC(C)(C)C=Cc3c2OC)ccc1OCCC1CCCCN1
• Target: Apoptosis,HSP
• Solubility: DMSO:40 mg/mL (85.73 mM)

Bioactivity

• In Vivo:
  NCT-58 (30 mg/kg; i.p.; every other day for 47 days) significantly impedes tumor growth, markedly reduces tumor weight, and effectively suppresses Trastuzumab-resistant tumor growth .
• In Vitro:
  NCT-58 treatment (0.1-10 μM; 72 hours) increases the number of early and late apoptotic cells in HER2-positive BT474 and SKBR3 cells. NCT-58 treatment (0.1-20 μM; 72 hours) dose-dependently reduces cell viability in HER2-positive BT474 and SKBR3 cells. NCT-58 treatment (2-10 μM; 72 hours) effectively reduced the levels of truncated p95HER2 and its phosphorylated form, as well as downregulation of Akt and phospho-Akt (Ser473) protein contents in JIMT-1 and MDA-MB-453 cells .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NCT 58, NCT58, NCT-58, HSP90

Compound Identifiers

PubChem CID

149033485